@ were enrolled into each of the @ g , @ g , or @ g plus @ g idarucizumab groups ( nine to idarucizumab and three to placebo in each group ) , and @ were enrolled into the @ g idarucizumab group ( eight to idarucizumab and three to placebo ) .